10-K: Coya Therapeutics Advances ALS, FTD Programs; Reports $21.2M Net Loss

Coya Therapeutics, a clinical-stage biotech, reported a $21.2 million net loss for 2025 while advancing its lead asset COYA 302 into Phase 2 for ALS and receiving IND acceptance for FTD, supported by a recent $11.1 million financing.

Summary

• Coya Therapeutics is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs) for neurodegenerative, autoimmune, and metabolic diseases.
• The company reported a net loss of $21.2 million for the year ended December 31, 2025, an increase from $14.9 million in 2024, with an accumulated deficit of $62.0 million.
• Collaboration revenue increased to $7.9 million in 2025 from $3.6 million in 2024, primarily due to milestone payments from Dr. Reddy's.
• Research and development expenses rose to $16.7 million in 2025 from $11.9 million in 2024, driven by clinical advancement of COYA 302 in ALS.
• The FDA accepted the Investigational New Drug (IND) application for COYA 302 for ALS in August 2025, and dosing of ALS patients in the Phase 2 ALSTARS Trial commenced in December 2025.
• In January 2026, the FDA also accepted the IND for COYA 302 for the treatment of frontotemporal dementia (FTD), with plans to advance it into a clinical trial.
• Positive complete results from an investigator-initiated proof-of-concept open-label study of COYA 302 in 9 FTD patients showed enhanced Treg numbers and function, cognitive function stability (MOCA scores unchanged, CDR-FTLD scores not significantly changed), and no serious adverse events over 22 weeks.
• Preclinical studies for COYA 303, a new product candidate for inflammatory diseases, demonstrated dual immunomodulatory activity and broad systemic/central anti-inflammatory effects in in vitro and in vivo models.
• Results from an investigator-initiated placebo-controlled Phase 2 POC trial of low-dose IL-2 (COYA 301) in 38 Alzheimer's Disease (AD) patients showed that the monthly (q4wks) regimen significantly expanded Tregs, improved CSF-soluble A42 levels, and showed a clinically meaningful 4.93-point improvement in ADAS-Cog14 score compared to placebo.
• The company completed an $11.1 million private placement in January 2026, with $10 million from Dr. Reddy's, intended to accelerate tech transfer and scale-up manufacturing for COYA 302 for ALS.
• Existing cash and the January 2026 financing are expected to fund operations into the second half of 2027, but substantial additional capital will be needed.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting significant clinical progress for COYA 302 in ALS and FTD, and promising Phase 2 data for COYA 301 in AD. The successful capital raise and increased collaboration revenue provide a solid financial footing for continued development, despite ongoing net losses typical for a clinical-stage biotech.

Positives

• Increased collaboration revenue to $7.9 million in 2025, up from $3.6 million in 2024, driven by milestone payments from Dr. Reddy's.
• FDA acceptance of IND for COYA 302 in ALS in August 2025, allowing the initiation of the Phase 2 ALSTARS Trial in December 2025.
• FDA acceptance of IND for COYA 302 in FTD in January 2026, paving the way for a new clinical trial.
• Positive complete results from an investigator-initiated proof-of-concept study of COYA 302 in 9 FTD patients, demonstrating enhanced Treg function, cognitive stability (MOCA scores unchanged, CDR-FTLD scores not significantly changed), and a favorable safety profile with no serious adverse events.
• Promising preclinical results for COYA 303, showing dual immunomodulatory and anti-inflammatory effects in both in vitro human immune cell models and in vivo mouse models.
• Positive results from a Phase 2 POC clinical trial of COYA 301 (LD IL-2) in 38 Alzheimer's Disease patients, where the monthly dosing regimen (q4wks) showed significant Treg expansion, improved CSF-soluble A42 levels, and a clinically meaningful 4.93-point improvement in ADAS-Cog14 score compared to placebo.
• Successful completion of an $11.1 million private placement in January 2026, including a $10 million investment from strategic collaborator Dr. Reddy's, which extends the cash runway into the second half of 2027 and supports commercial readiness for COYA 302 for ALS.
• Nobel Prize in Physiology or Medicine awarded to Dr. Shimon Sakaguchi in 2025, a member of the company's Scientific Advisory Board, for his discovery of Tregs, validating the company's core therapeutic focus.

Negatives

• Net loss increased to $21.2 million for the year ended December 31, 2025, from $14.9 million in 2024.
• Accumulated deficit reached $62.0 million as of December 31, 2025.
• The company has no products approved for commercial sale and has never generated revenue from product sales.
• Significant operating losses are expected to continue for the foreseeable future as product candidates advance through development and clinical trials.
• Substantial additional capital will be needed beyond the second half of 2027 to support continuing operations and growth strategy.
• In a preclinical lupus nephritis model in mice, COYA 201 (Treg exosome product candidate) caused fatalities in 6 out of 12 animals when administered at extremely high doses (1x10^11 exosomes, ten times the low dosage level), although it was well tolerated at lower doses.
• The primary endpoint of proteinuria was not met in the preclinical lupus nephritis model for COYA 201.
• The company does not currently own, lease, or operate its own principal laboratory, R&D, or manufacturing facility, relying on third parties, which could lead to delays and increased costs.

Risks

• The company is a clinical-stage biopharmaceutical company with no products approved for commercial sale and has incurred significant losses since inception, with expectations of continued losses for the foreseeable future.
• Substantial additional capital will be required, and there is no assurance it will be available on acceptable terms or at all, which could limit future clinical trials and product development and threaten long-term viability.
• Future issuance of additional securities, including upon exercise of outstanding options and warrants, could dilute existing stockholders and negatively affect stock price.
• Public health outbreaks, epidemics, or pandemics (such as COVID-19) could materially adversely affect business, including preclinical studies and clinical trials.
• Substantial delays may be encountered in planned clinical trials, or the company may not be able to conduct or complete clinical trials on expected timelines, if at all.
• Reliance on third parties to manufacture product candidates increases the risk of delays, prevention, or impairment of preclinical development, clinical development, and potential commercialization.
• The business is subject to extensive and costly government regulation, and failure to obtain approval or comply with post-approval requirements could lead to penalties.
• Even if regulatory approval is obtained, product candidates may not be accepted by the market.
• The company faces intense competition from companies with greater resources, which may hinder its ability to compete effectively.
• Global events, including political instability, natural disasters, terrorism, and wars, may negatively impact the business.
• Claims of infringing on third-party intellectual property rights could lead to costly and time-consuming litigation.
• The company's ability to use net operating loss carryovers and certain other tax attributes may be limited due to ownership changes (Section 382 limitation).
• Positive results from early studies of product candidates are not necessarily predictive of later study results, and failure to replicate positive results could prevent successful development and commercialization.
• Undesirable side effects caused by product candidates could interrupt, delay, or halt clinical trials, or result in a more restrictive label or denial of regulatory approval.
• Failure to satisfy FDA's Chemistry, Manufacturing and Control (CMC) requirements could delay or deny approval.
• Inability to obtain or maintain adequate insurance coverage for all potential liabilities could expose the company to unrecoverable risks.
• The business involves the use of hazardous materials, and non-compliance with environmental laws or accidental contamination could lead to costly clean-up and liabilities.
• Computer system interruptions, cyber-attacks, or security breaches could significantly disrupt product development programs and business operations.
• Manufacturing processes are complex and susceptible to product loss, failure, or variation, which could delay or prevent sufficient supply for clinical trials or commercialization.
• Changes in trade policies, including tariffs or other restrictions, could impact the ability to obtain raw materials and components, increasing costs or causing supply chain disruptions.
• Reliance on third parties to store Treg cells and other products means damage or loss could cause delays in replacement and harm the business.
• The company has not yet developed a validated methodology for freezing and thawing large quantities of Treg cells, which is crucial for storage and distribution, and long-term stability of cryopreserved cells is unproven.
• Termination of the license agreement with The Methodist Hospital could lead to loss of rights to key components of Treg Modalities.
• Duration of patent terms may be inadequate, and expiration of patents could lead to increased competition.
• Changes in U.S. patent law or other jurisdictions could decrease the certainty of obtaining patents and diminish their value.
• Failure to obtain or enforce assignments of intellectual property rights from employees and contractors could lead to loss of valuable IP.
• Inadequate prevention of trade secret disclosure could diminish the value of technology and products.

Future Outlook

The company expects to continue incurring significant expenses and operating losses as it advances product candidates through development and clinical trials, and seeks regulatory approval. If marketing approval is obtained, significant commercialization expenses related to manufacturing, marketing, sales, and distribution are anticipated. Substantial additional capital will be needed to support continuing operations and growth strategy beyond the second half of 2027, with financing planned through equity, debt, or strategic collaborations. The company intends to complete enrollment in the ALSTARS trial for ALS in the second half of 2026 and advance COYA 302 for FTD into a clinical trial. Partnerships and grants will be pursued to advance the COYA 303 program, and business development opportunities will be sought for COYA 301 and COYA 302.

Management Comments

• We believe we have expertise in three distinct potential therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
• We believe COYA 302 is the most clinically advanced of what we hope will be a family of combination therapies that all feature our LD IL-2. Given the growing list of indications for which we are developing it, we can now refer to COYA 302 as a Pipeline in a Product.
• Our research and clinical efforts have led us to believe that combination biologics using our LD IL-2 as a backbone modality could be an effective way to treat neurodegenerative conditions that are inherently driven by a complexity of pathways.
• We believe our findings have also established mechanistic benefits of combination biologics to address Treg dysfunction as well as highlighted important advantages of scalability and cost.
• We believe our data demonstrates the anti-inflammatory activity of Treg exosomes in in vitro assays and in vivo animal models of acute inflammation and ALS, following intravenous and intranasal administration.
• We believe our research demonstrates that Treg exosomes exhibit greater anti-inflammatory potency than mesenchymal exosomes.
• We believe this proprietary technology sets the foundation to produce targeted Treg exosome potential therapeutics that are directed to epitopes... while delivering growth factors, drugs or other cargo, representing an innovative technology that could be advantageous relative to other Treg directed potential therapeutic modalities.
• We believe that our investigational and proprietary biologic combination therapy, COYA 302, with a dual immunomodulatory mechanism of action represents a next generation approach that has competitive advantages over monotherapy approaches that target a single pathway to treating inflammatory disorders, which are driven by complex and multi-factorial pathways.
• We believe our Treg exosomes are significantly more potent in suppressing inflammation than mesenchymal cell derived exosomes.

Industry Context

StockSavvy.ai notes that Coya Therapeutics operates in the highly competitive and rapidly evolving cellular immunotherapy and neurodegenerative disease markets. The company's focus on Regulatory T cells (Tregs) positions it within an emerging therapeutic area, further validated by the 2025 Nobel Prize awarded to Dr. Shimon Sakaguchi, a member of Coya's Scientific Advisory Board, for his discovery of Tregs. While several competitors are developing IL-2 formulations (e.g., Amgen, Nektar, Merck, Xencor, Cue Biopharma, Moderna, ILTOO Pharma) and Treg-based cellular therapies (e.g., Abata Therapeutics, Sonoma Biotherapeutics, Sangamo Therapeutics, TRex Bio, Mozart Therapeutics, GentiBio, Kyverna Therapeutics, Cellenkos, AZ Therapies, Quell Therapeutics), Coya claims a unique position with its Treg-derived exosome technology, stating no other direct competitors in this specific modality. The company's strategy of developing combination biologics with LD IL-2 as a backbone aims to differentiate it from monotherapy approaches, addressing the complex pathways of neurodegenerative conditions. The strategic collaboration and investment from Dr. Reddy's Laboratories for COYA 302 in ALS highlights external validation and potential for broader market reach, contrasting with smaller biotechs that often struggle for funding and partnerships.

Comparison to Industry Standards

• Coya's COYA 302 (LD IL-2 + CTLA4-Ig) is positioned as a next-generation approach with competitive advantages over monotherapy treatments for inflammatory disorders, which are often driven by complex, multi-factorial pathways.
• In the ALS space, Coya competes with companies like Ionis Pharmaceuticals (in collaboration with Biogen), Neurizon Therapeutics, Alchemab Therapeutics (in partnership with Eli Lilly), Athira Pharma, NeuroSense Therapeutics, Amylyx Pharmaceuticals, Medicinova, Inc., and Clene Nanomedicine, all developing drugs for ALS.
• For biologic approaches enhancing Tregs using IL-2 formulations, Coya faces competition from Amgen (IL-2 mutein for GVHD and autoimmune diseases), Nektar Therapeutics (Pegylated IL-2 for autoimmune diseases), Merck (IL-2 mutein for autoimmune diseases), Xencor (IL-2 Fc Fusion Protein for autoimmune diseases), Cue Biopharma (IL-2 bispecific for GVHD and autoimmune diseases), Moderna (LNP encapsulated mRNA based therapeutic encoding IL-2 for autoimmune diseases), and ILTOO Pharma (low dose IL-2 formulation).
• In Treg-based cellular therapeutics, competitors include Abata Therapeutics (CAR Treg for autoimmune diseases), Sonoma Biotherapeutics (CAR Treg for autoimmune diseases), Sangamo Therapeutics (CAR Treg for Renal Disease, IBD), TRex Bio (Treg cell therapy for Immunology/Inflammation), Mozart Therapeutics (CD8 Treg cell modulators for Celiac Disease/IBD), GentiBio (Treg cell therapy generated from T-effector cells for T1 Diabetes), Kyverna Therapeutics (Autologous and Allogeneic cell therapies for autoimmune diseases), Cellenkos (Allogeneic umbilical cord blood Tregs for multiple conditions), AZ Therapies (Allogeneic CAR Tregs for CNS Diseases), and Quell Therapeutics (Autologous CAR Tregs for liver transplantation, T1 Diabetes and ALS).
• Coya claims a unique competitive advantage with its Treg-derived exosomes, stating there are no other direct Treg-derived exosome competitors, though other cell-derived exosome competitors exist (e.g., Evox Therapeutics, Capricor Therapeutics, Exopharm, Rion). Coya believes its Treg exosomes are significantly more potent than mesenchymal cell-derived exosomes.
• The investigator-initiated POC study in ALS showed no decline or minimal decline in ALSFRS-R scores at 24 and 48 weeks, respectively, after treatment initiation, compared to a mean decline of -1.1 points/month prior to treatment, indicating clinically meaningful amelioration in disease progression. This 24-week timepoint is benchmarked in ALS studies.
• In the AD Phase 2 POC trial, the LD IL-2 q4wks regimen showed a clinically meaningful 4.93-point improvement in ADAS-Cog14 score compared to placebo, which worsened by 4.480 points from baseline. This suggests a significant positive effect on cognitive function.

Management Changes

Corporate Governance

Legal Proceedings

• No material pending litigation to which the company is a party or to which its property is subject.
• Litigation, if it arises, can be costly, time-consuming, and divert management's attention from important business matters and initiatives, negatively impacting overall operations.

Related Party Transactions

• Employment Agreements: The company has employment agreements with its executive officers (Arun Swaminathan, David Snyder, Fred Grossman, Howard Berman) detailing base salary, annual bonus eligibility, and equity awards.
• Indemnification Agreements: The company has entered into indemnification agreements with all current directors and executive officers, requiring indemnification to the fullest extent permitted under Delaware law and advancement of expenses.
• Dr. Reddy's Laboratories: Dr. Reddy's is a strategic collaborator and investor. In January 2026, Dr. Reddy's Laboratories, Inc. provided $10 million of the $11.1 million gross proceeds from a private placement. Dr. Reddy's also holds 2,272,727 shares of common stock, representing 9.7% beneficial ownership as of February 28, 2026.
• Greenlight Capital: Greenlight Capital (DME Capital Management, LP d/b/a Greenlight Capital) beneficially owns 2,335,540 shares, representing 9.9% beneficial ownership as of February 28, 2026.
• The Methodist Hospital: The company has an Amended and Restated Patent Know How and License Agreement with The Methodist Hospital and a Sponsored Research Agreement with Houston Methodist Research Institute (an affiliate of Methodist). Milestone payments were incurred to Methodist in 2025 ($0.1 million) in connection with IND Milestones and Dosing Milestone.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises, but also potential for increased value if product candidates achieve regulatory approval and commercial success. The market price of common stock may be volatile.
• Employees: The company plans to increase employee headcount significantly as it expands clinical development and commercialization efforts, offering growth opportunities. Stock-based compensation is a key part of executive and director compensation.
• Customers (Future Patients): Development of novel therapies for serious neurodegenerative, autoimmune, and metabolic diseases aims to address high unmet medical needs, potentially offering new treatment options.
• Suppliers/Partners: Continued reliance on third-party manufacturers, CROs, and research institutions for development and manufacturing, indicating ongoing business for these partners. Strategic collaborations, like with Dr. Reddy's, are crucial for funding and commercialization.
• Creditors: The company's ongoing net losses and need for substantial additional capital present a risk, though current cash runway extends into H2 2027.

Next Steps

• Complete enrollment in the ALSTARS trial (Phase 2 study of COYA 302 for ALS) in the second half of 2026.
• Advance COYA 302 for FTD into a randomized, double-blind, placebo-controlled clinical trial.
• Pursue business development opportunities and/or grants to advance the COYA 303 program through IND enabling studies.
• Explore the utility of COYA 302 as a therapeutic for other neurodegenerative diseases, including Parkinson's Disease (PD) and Alzheimer's Disease (AD).
• Seek partnerships with other pharmaceutical and biotechnology companies for COYA 301 combination therapies.
• Continue scientific and preclinical validation of exosomes as a therapeutic modality in collaboration with Houston Methodist Hospital.
• Evaluate data from preclinical studies of COYA 201 in different animal models to select a potential clinical indication for human studies.
• Work on the characterization of Exosome-Polymer Hybrids (EPHs) for COYA 206 and plan target validation to select product candidates and indications.
• Raise substantial additional capital through equity, debt financings, or strategic transactions to support continuing operations and growth strategy beyond the second half of 2027.
• Discuss and agree on terms for a commercial supply agreement for COYA 302 with Dr. Reddy's.

Key Dates

Recommendation

Coya Therapeutics has demonstrated significant clinical progress with its lead asset COYA 302 for ALS and FTD, and promising Phase 2 data for COYA 301 in Alzheimer's Disease. The recent capital raise, including strategic investment from Dr. Reddy's, provides a cash runway into the second half of 2027, mitigating immediate liquidity concerns. However, the company remains in a clinical stage with no approved products, incurring substantial net losses, and will require significant additional funding for future development and commercialization. While the scientific validation of Tregs and early clinical signals are encouraging, the inherent risks of drug development, intense competition, and the need for further capital suggest a 'hold' recommendation. Investors should monitor upcoming clinical trial results and future financing activities closely.

Keywords

Coya Therapeutics, COYA, Biotechnology, Clinical-stage, Regulatory T cells, Tregs, Neurodegenerative diseases, Autoimmune diseases, Metabolic diseases, ALS, Amyotrophic Lateral Sclerosis, FTD, Frontotemporal Dementia, Alzheimer's Disease, AD, Parkinson's Disease, PD, COYA 302, Low-dose IL-2, CTLA4-Ig, COYA 303, GLP-1 RA, COYA 301, Treg-enhancing biologics, Treg-derived exosomes, Autologous Treg cell therapy, ALSTARS Trial, FDA IND, Clinical Trials, Biologics License Application, BLA, Orphan Drug Designation, Intellectual Property, Dr. Reddy's Laboratories, Houston Methodist Hospital, Financial Performance, Net Loss, Cash Runway, Capital Raise, Biopharmaceutical, Immunomodulation, Drug Development